- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ( Listing Regulations ), we wish to inform you that the Company is in receipt of an Adjudication Order passed by the...
Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaper advertisement published today i.e 25th August, 2026, regarding the opening of special window for re-lodgement of the transfer requests of...
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilization of proceeds of Qualified Institutions Placement ( QIP ) for the quarter ended...
Wockhardt launched its Antibiotic Academy, a key initiative to tackle multidrug resistance. This platform fosters scientific dialogue and education for medical professionals, aiming to improve patient outcomes and strengthen the company's position in the critical fight against superbugs.